A dual-nano drug system capable of potential interference and free radical scavenging to treat bacterial nephritis
Source abstract
Abstract
Bacterial nephritis is a bacterial infection that affects unilateral or bilateral kidneys. Its clinical treatment is limited due to bacterial infection and high oxidative stress, along with a lack of effective treatment strategies. This study aimed to develop a novel dual-nano drug system (TA@Ce3+ + CS-PL) for its potential therapeutic effects in bacterial nephritis. This system combines potential interference and free radical scavenging capabilities to provide synergistic antibacterial and antioxidant stress therapies. Electron spin resonance spectra revealed that TA@Ce3+ significantly reduced the signals of reactive oxygen species. Live-dead cell staining results indicated that the dual-nanosystem can effectively kill Staphylococcus aureus and Pseudomonas aeruginosa and is no toxicity. Hematoxylin and eosin staining results confirmed that the dual-nanosystem could protect mouse kidney tissue from bacterial infection and inflammatory effects in vitro. These results suggest that the TA@Ce3+ + CS-PL dual-nanosystem exhibited significant antibacterial and antioxidant stress effects on bacterial nephritis in vitro. It is non-toxic to normal cells, suggesting it as a potential therapeutic candidate for bacterial nephritis.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Quantum Dots Synthesis And Properties
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Chongqing University Fuling Hospital, Chongqing University
Shanghai Geriatric Medical Center
Fudan University
Funding
Chongqing Fuling District Science · Health Joint Medical Research Project
References (23)
Show source-provided references
1. 10.1038/s41467-018-06799-610.1038/s41467-018-06799-6 ↗
2. 10.1016/j.kint.2019.06.00510.1016/j.kint.2019.06.005 ↗
3. 10.1126/scitranslmed.aaf128310.1126/scitranslmed.aaf1283 ↗
4. 10.1001/jamanetworkopen.2020.395110.1001/jamanetworkopen.2020.3951 ↗
5. 10.1038/s41564-021-00920-010.1038/s41564-021-00920-0 ↗
6. 10.1080/10667857.2024.238197810.1080/10667857.2024.2381978 ↗
7. 10.1080/10667857.2024.233584810.1080/10667857.2024.2335848 ↗
8. 10.1080/10667857.2024.242853210.1080/10667857.2024.2428532 ↗
9. 10.1080/10667857.2024.230959610.1080/10667857.2024.2309596 ↗
10. 10.1080/10667857.2024.239566310.1080/10667857.2024.2395663 ↗
11. 10.1080/10667857.2024.238745410.1080/10667857.2024.2387454 ↗
12. 10.1080/10667857.2022.214116910.1080/10667857.2022.2141169 ↗
13. 10.1016/j.carbpol.2022.12048510.1016/j.carbpol.2022.120485 ↗
14. 10.1038/s41564-018-0164-010.1038/s41564-018-0164-0 ↗
15. 10.1002/advs.20200362710.1002/advs.202003627 ↗
16. 10.1002/adfm.20230314710.1002/adfm.202303147 ↗
17. 10.1002/advs.20210036810.1002/advs.202100368 ↗
18. 10.1136/jitc-2022-00622210.1136/jitc-2022-006222 ↗
19. 10.1016/j.redox.2021.10204610.1016/j.redox.2021.102046 ↗
20. 10.1172/JCI15535010.1172/JCI155350 ↗
21. 10.7150/thno.4760110.7150/thno.47601 ↗
22. 10.7150/thno.7863910.7150/thno.78639 ↗
23. 10.1021/acsnano.8b0199410.1021/acsnano.8b01994 ↗